Evaluation of the genotoxicity of cisplatin, paclitaxel and 5-fluorouracil combined treatment in the Drosophila wing-spot test

Food and Chemical Toxicology

Volumn 48, Issue 11, 2010, Pages 3120-3124

  Danesi, Cristiane Cademartori ^a,b   Bellagamba, Bruno Corrêa ^a   Dihl, Rafael Rodrigues ^a   Andrade, Heloísa Helena Rodrigues de ^a   Cunha, Kênya Silva ^c   Lehmann, Mauricio ^a  

^a UNIVERSIDADE LUTERANA DO BRASIL   (Brazil)

^b FEDERAL UNIVERSITY OF SANTA MARIA   (Brazil)

^c FEDERAL UNIVERSITY OF GOIÁS   (Brazil)

Author keywords

Cisplatin; Drosophila melanogaster; Genotoxicity; Head and neck cancer; Paclitaxel; SMART

Indexed keywords

CISPLATIN; DNA; FAULDFLUOR; FLUOROURACIL; PACLITAXEL; PLATISTINE; UNCLASSIFIED DRUG;

ANEUPLOIDY; ARTICLE; CELL PROLIFERATION; CHROMOSOME MUTATION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DNA DAMAGE; DROSOPHILA MELANOGASTER; DRUG POTENTIATION; GENETIC RECOMBINATION; GENOTOXICITY; GENOTYPE; MONOTHERAPY; MUTAGENICITY; NONHUMAN; SOMATIC MUTATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CISPLATIN; CROSSES, GENETIC; DROSOPHILA; DRUG COMBINATIONS; FEMALE; FLUOROURACIL; GENETIC MARKERS; LARVA; MALE; MUTAGENICITY TESTS; MUTAGENS; MUTATION; PACLITAXEL; RECOMBINATION, GENETIC; WING;

DROSOPHILA MELANOGASTER;

EID: 77957375130     PISSN: 02786915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fct.2010.08.005     Document Type: Article

References (48)

1. Adamo V., Ferraro G., Pergolizzi S., Sergi C., Laudani A., Settineri N., Alafaci E., Scimone A., Spano F., Spitaleri G. Paclitaxel and cisplatin in patients with recurrent and metastatic head and neck squamous cell carcinoma. Oral Oncol. 2004, 40:525-531.
2. Aziz N.M. Cancer survivorship research: state of knowledge, challenges and opportunities. Acta Oncol. 2007, 46:417-432.
3. Benasso M., Numico G., Rosso R., Merlano M., Ricci I., Gentile A. Chemotherapy for relapsed head and neck cancer: paclitaxel, cisplatin and 5-fluorouracil in chemotherapy naive patients. A dose-finding study. Semin. Oncol. 1997, 24:46-50.
4. Cruz J.J., Ocaña A., Navarro M., Barco E.D., Fonseca E. New options in the treatment of locally advanced head and neck cancer: role for induction chemotherapy. Cancer Treat. Rev. 2008, 34:268-274.
5. Cunha K.S., Reguly M.L., Graf U., Andrade H.H. Taxanes: the genetic toxicity of paclitaxel and docetaxel in somatic cells of Drosophila melanogaster. Mutagenesis 2001, 16:79-84.
6. Danesi, C.C., Bellagamba, B.C., Dihl, R.R., Andrade, H.H.R., Cunha, K.S., Lehmann, M., Submitted for publication. Genotoxicity testing of combined treatment with cisplatin, bleomycin and 5-fluorouracil in somatic cells of Drosophila melanogaster.
7. Danesi C.C., Bellagamba B.C., Dihl R.R., Andrade H.H.R., Cunha K.S., Spanó M.A., Reguly M.L., Lehmann M. Mutagenic evaluation of combined paclitaxel and cisplatin treatment in somatic cells of Drosophila melanogaster. Mutat. Res. 2010, 696:139-143.
8. Digue L., Orsière T., De Méo M., Mattéi M.G., Depetris D., Duffaud F., Favre R., Botta A. Evaluation of the genotoxic activity of paclitaxel by the in vitro micronucleus test in combination with fluorescent in situ hybridization of a DNA centromeric probe and the alkaline single cell gel electrophoresis technique (comet assay) in human T-lymphocytes. Environ. Mol. Mutagen. 1999, 34:269-278.
9. Frei H., Würgler F.E. Induction of somatic mutation and recombination by four inhibitors of eukaryotic topoisomerases assayed in the wing spot test of Drosophila melanogaster. Mutagenesis 1996, 11:315-325.
10. Frei H., Würgler F.E. Optimal experimental design and sample size for the statistical evaluation of data from somatic mutation and recombination tests (SMART) in Drosophila. Mutat. Res. 1995, 334:247-258.
11. Frei H., Würgler F.E. Statistical methods to decide whether mutagenicity test data from Drosophila assays indicate a positive, negative or inconclusive result. Mutat. Res. 1988, 203:297-308.
12. Frei H., Clements J., Howe D., Würgler F.E. The genotoxicity of the anticancer drug mitoxantrone in somatic and germ-cells of Drosophila melanogaster. Mutat. Res. 1992, 279:21-33.
13. García Sar D., Montes-Bayón M., Aguado Ortiz L., Blanco-González E., Sierra L.M., Sanz-Medel A. In vivo detection of DNA adducts induced by cisplatin using capillary HPLC-ICP-MS and their correlation with genotoxic damage in Drosophila melanogaster. Anal. Bioanal. Chem. 2008, 390:37-44.
14. Graf U., Würgler F.E., Katz A.J., Frei H., Juon H., Hall C.B., Kale P.G. Somatic mutation and recombination test in Drosophila melanogaster. Mutat. Res. 1984, 271:59-67.
15. Graf U., Frei H., Kägi A., Katz A.J., Würgler F.E. Thirty compounds tested in the Drosophila wing spot test. Mutat. Res. 1989, 222:359-373.
16. Haveman J., Castro Kreder N., Rodermond H.M., van Bree C., Franken N.A., Stalpers L.J., Zdzienicka M.Z., Peters G.J. Cellular response of X-ray sensitive hamster mutant cell lines to gemcitabine, cisplatin and 5-fluorouracil. Oncol. Rep. 2004, 12:187-192.
17. Henderson T.O., Whitton J., Stovall M., Mertens A.C., Mitby P., Friedman D., Strong L.C., Hammond S., Neglia J.P., Meadows A.T., Robison L., Diller L. Secondary sarcomas in childhood cancer survivors: a report from the childhood cancer survivor study. J. Natl. Cancer Inst. 2007, 99:300-308.
18. Hitt R., Lopez-Pousa A., Martinez-Trufero J., Escrig V., Carles J., Rizo A., Isla D., Vega M.E., Marti J.L., Lobo F., Pastor P., Valenti V., Belon J., Sanchez M.A., Chaib C., Pallares C., Anton A., Cervantes A., Paz-Ares L., Cortes-Funes H. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J. Clin. Oncol. 2005, 23:8636-8645.
19. Honma M., Hayashi M., Shimada H., Tanaka N., Wakuri S., Awogi T., Yamamoto K.I., Kodani N., Nishi Y., Nakadate M., Sofuni T. Evaluation of the mouse lymphoma tk assay (microwell method) as an alternative to the in vitro chromosomal aberration test. Mutagenesis 1999, 14:5-22.
20. Hunter K.D., Parkinson E.K., Harrison P.R. Profiling early head and neck cancer. Nat. Rev. Cancer 2005, 5:127-135.
21. Katz A.J. Genotoxic effects of cisplatin in somatic tissue of Drosophila melanogaster. Environ. Mol. Mutagen. 1987, 10:197-203.
22. Katz A.J. Modulation by temperature of the genotoxic potency of cisplatin in Drosophila wing spot assay. Teratog. Carcinog. Mutagen. 1998, 18:93-100.
23. Kies M.S. Induction chemotherapy for head and neck squamous cell carcinomas (SCCHN). Curr. Treat. Options Oncol. 2007, 8:252-260.
24. Kumar N. Taxol-induced polymerization of purified tubulin. J. Biol. Chem. 1981, 256:10435-10441.
25. Lee M., Kwon J., Chung M.K. Enhanced prediction of potential rodent carcinogenicity by utilizing comet assay and apoptotic assay in combination. Mutat. Res. 2003, 541:9-19.
26. The genome of Drosophila melanogaster. Academic Press, New York 1992, 1133p.
27. Lobert S., Vulevic B., Correia J.J. Interaction of vinca alkaloids with tubulin: a comparison of vinblastine, vincristine, and vinorelbine. Biochemistry 1996, 35:6806-6814.
28. Lorge E., Thybaud V., Aardema M.J., Oliver J., Wakata A., Lorenzon G., Marzin D. SFTG international collaborative study on in vitro micronucleus test I. General conditions and overall conclusions of the study. Mutat. Res. 2006, 607:13-36.
29. Matuo R., Sousa F.G., Escargueil A.E., Grivicich I., Garcia-Santos D., Chies J.A., Saffi J., Larsen A.K., Henriques J.A. 5-Fluorouracil and its active metabolite FdUMP cause DNA damage in human SW620 colon adenocarcinoma cell line. J. Appl. Toxicol. 2009, 29:308-316.
30. Matuo R., Sousa F.G., Escargueil A.E., Soares D.G., Grivicich I., Saffi J., Larsen A.K., Henriques J.A.P. DNA repair pathways involved in repair of lesions induced by 5-fluorouracil and its active metabolite FdUMP. Biochem. Pharmacol. 2010, 79:147-153.
31. McClendon A.K., Osheroff N. DNA topoisomerase II, genotoxicity, and cancer. Mutat. Res. 2007, 623:83-97.
32. Merlano M., Russi E.G., Numico G., Colantonio I., Garrone O., Pelissero A., Granetto C., Gasco M., Di Costanzo G., Heouaine A., Vigna Taglianti R., Cipolat M. Paclitaxel, cisplatin, 5-fluorouracil and radiotherapy in the management of advanced squamous cell carcinoma of the head and neck: a phase II trial. Radiother. Oncol. 2005, 75:193-196.
33. Meyers M., Hwang A., Wagner M.W., Bruening A.J., Veigl M.L., Sedwick W.D., Boothman D.A. A role for DNA mismatch repair in sensing and responding to fluoropyrimidine damage. Oncogene 2003, 22:7376-7388.
34. Miyamoto C.T., Sant'Anna J.R., Franco C.C.S., Castro-Prado M.A.A. Genotoxicity (mitotic recombination) of the cancer chemotherapeutic agents cisplatin and cytosine arabinoside in Aspergillus nidulans. Food Chem. Toxicol. 2007, 45:1091-1095.
35. Nowosielska A., Calmann M.A., Zdraveski Z., Essigmann J.M., Marinus M.G. Spontaneous and cisplatin-induced recombination in Escherichia coli. Mutat. Res. 2004, 3:719-728.
36. Nowosielska A., Marinus M.G. Cisplatin induces DNA double-strand break formation in Escherichia coli dam mutants. DNA Repair (Amst) 2005, 4:773-781.
37. Ohuchida A., Furukawa A., Yoshida J., Watanabe M., Aruga F., Miwa Y., Shinkawa K., Kinae N. Micronucleus assays on 5-fluorouracil and 6-mercaptopurine with mouse peripheral blood reticulocytes. Mutat. Res. 1992, 278:139-143.
38. Oka H., Ikeda K., Yoshimura H., Ohuchida A., Honma M. Relationship between p53 status and 5-fluorouracil sensitivity in 3 cell lines. Mutat. Res. 2006, 606:52-60.
39. Oliveira R.J., Baise E., Mauro M.O., Pesarini J.R., Matuo R., da Silva A.F., Ribeiro L.R., Mantovani M.S. Evaluation of chemopreventive activity of glutamine by the comet and the micronucleus assay in mice's peripheral blood. Environ. Toxicol. Pharmacol. 2009, 28:120-124.
40. Peters G.J., van der Wilt C.L., van Moorsel C.J., Kroep J.R., Bergman A.M., Ackland S.P. Basis for effective combination cancer chemotherapy with antimetabolites. Pharmacol. Ther. 2000, 87:227-253.
41. Ringel I., Horwitz S.B. Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol. J. Natl. Cancer Inst. 1991, 83:288-291.
42. Rodríguez-Arnaiz R., Sortibrán A.C., Téllez G.O. Detection of mitotic recombination and sex chromosome loss induced by adriamycin, chlorambucil, demecolcine, paclitaxel and vinblastine in somatic cells of Drosophila melanogaster in vivo. Mutagenesis 2004, 19:121-127.
43. Seifried H.E., Seifried R.M., Clarke J.J., Junghans T.B., San R.H. A compilation of two decades of mutagenicity test results with the Ames Salmonella typhimurium and L5178Y mouse lymphoma cell mutation assays. Chem. Res. Toxicol. 2006, 19:627-644.
44. Silva M.J., Costa P., Dias A., Valente M., Louro H., Boavida M.G. Comparative analysis of the mutagenic activity of oxaliplatin and cisplatin in the Hprt gene of CHO cells. Environ. Mol. Mutagen. 2005, 46:104-115.
45. Snyder R.D. An update on the genotoxicity and carcinogenicity of marketed pharmaceuticals with reference to in silico predictivity. Environ. Mol. Mutagen. 2009, 50:435-450.
46. Tokunaga E., Oda S., Fukushima M., Maehara Y., Sugimachi K. Differential growth inhibition by 5-fluorouracil in human colorectal carcinoma cell lines. Eur. J. Cancer 2000, 36:1998-2006.
47. Woynarowski J.M., Chapman W.G., Napier C., Herzig M.C.S., Juniewicz P. Sequence- and region-specificity of oxaliplatin adducts in naked and cellular DNA. Mol. Pharmacol. 1998, 54:770-777.
48. Yajima N., Kondo K., Morita K. Reverse mutation tests in Salmonella typhimurium and chromosomal aberration tests in mammalian cells in culture on fluorinated pyrimidine derivatives. Mutat. Res. 1981, 88:241-254.